X
Upload your Marketing & Sales content on your company Virtual Booth, click HERE.
Details:
The collaboration aims to develop and commercialize ZB-O12 (obexelimab), an investigational bifunctional, non-cytolytic, humanized monoclonal antibody that binds CD19 and FcγRIIb, for autoimmune diseases in Japan, South Korea, Taiwan, Singapore, Hong Kong and Australia.
Lead Product(s): Obexelimab
Therapeutic Area: Immunology Product Name: ZB-O12
Highest Development Status: Phase IIIProduct Type: Large molecule
Partner/Sponsor/Collaborator: Bristol Myers Squibb
Deal Size: Undisclosed Upfront Cash: $50.0 million
Deal Type: Collaboration September 05, 2023
Details:
ZB-O12 (obexelimab) is an investigational Phase 3-stage, novel bifunctional antibody with first-in-class potential that inhibits B-cell lineages that express CD19 and generates an encouraging treatment effect in patients with multiple autoimmune diseases.
Lead Product(s): Obexelimab
Therapeutic Area: Immunology Product Name: ZB-O12
Highest Development Status: Phase IIIProduct Type: Large molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable January 11, 2023
Details:
ZB-O12 (obexelimab) is a novel bifunctional antibody with first-in-class potential that inhibits B-cell lineages that express CD19. Simultaneous binding to CD19 and FcƳRIIB by obexelimab mimics a natural antigen-antibody complex and down-regulates B-cell activity.
Lead Product(s): Obexelimab
Therapeutic Area: Immunology Product Name: ZB-O12
Highest Development Status: Phase IIIProduct Type: Large molecule
Partner/Sponsor/Collaborator: Enavate Sciences
Deal Size: $118.0 million Upfront Cash: Undisclosed
Deal Type: Series B Financing November 07, 2022
Details:
Zenas BioPharma licensed the exclusive rights to develop, manufacture and commercialize ZB001 (Viridian VRDN-001) and other compounds targeting IGF-1R in non-oncology indications in the greater China area from Viridian Therapeutics in 2020.
Lead Product(s): ZB001
Therapeutic Area: Immunology Product Name: VRDN-001
Highest Development Status: IND EnablingProduct Type: Large molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable August 01, 2022
Details:
ZB001 (Viridian VRDN-001) is a differentiated humanized monoclonal antibody targeting insulin-like growth factor 1 receptor (IGF-1R) for the treatment of TED.
Lead Product(s): ZB001
Therapeutic Area: Immunology Product Name: VRDN-001
Highest Development Status: IND EnablingProduct Type: Large molecule
Partner/Sponsor/Collaborator: Viridian Therapeutics
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable May 12, 2022
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results] 
Market Place
